Tags: OncoMed | Celgene | cancer | drugs

OncoMed and Celgene to Jointly Develop Six Cancer Drugs

Tuesday, 03 Dec 2013 09:17 AM

OncoMed Pharmaceuticals Inc. said Celgene Corp. would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million.

OncoMed's stock rose 68 percent to $23.50 in premarket trading on Tuesday.

OncoMed is eligible to receive up to $3 billion in option and milestone payments if Celgene's option to license worldwide rights is exercised and approved, the companies said in a statement.

Celgene will also buy about $22.25 million of OncoMed's common stock for $15.13 per share, an 8 percent premium to OncoMed's closing on Monday.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
OncoMed Pharmaceuticals Inc. said Celgene Corp. would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million.
OncoMed,Celgene,cancer,drugs
92
2013-17-03
Tuesday, 03 Dec 2013 09:17 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved